Introduction {#sec0001}
============

Biologic disease modifying agents (DMARD) are now an integral component of treatment guidelines for rheumatoid arthritis (RA) and other inflammatory arthritis, and currently more than one-third of RA patients use biologics [@bib0001], [@bib0002], [@bib0003]. Several clinical trials have demonstrated the efficacy of biologics in reducing disease activity as well as retarding disease progression and with an increased emphasis on early and tight control of the disease, the use of biologic DMARDs is becoming more common [@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0008], [@bib0009], [@bib0010], [@bib0011], [@bib0012], [@bib0013], [@bib0014]. Adoption of biologic agents for RA treatment, however, comes at a price. Biologic agents are substantially more expensive per dose than conventional DMARDs, adding an additional \$20,000 per year to direct medical care costs (\$12,509 if not on a biologic versus \$36,053 if on a biologic) in the United States. While the cost of drugs in RA patients using conventional agents is \$1500--2000 annually, the cost of drugs in RA patients using biologics is as much as \$30,000 a year [@bib0015]. Biologic agents administered as an intravenous infusion have a facility/administration fee associated with it which further adds to the cost of care of RA.

RA is twice as prevalent in older population as compared to young (2% versus 1%). And given the chronic nature of the disease and our aging population, the number of elderly RA patients is expected to rise [@bib0016], [@bib0017], [@bib0018], [@bib0019]. Medicare is largest payer for healthcare of older individuals. A study conducted by McCormick et al noted more than 2-fold increase in Medicare and Medicaid spending on biologic disease modifying agents commonly used for treatment of rheumatic diseases which was largely driven by post-marketing increases in drug price [@bib0020]. In the context of increasing spending on biologic DMARDs, we compared the trends in Medicare spending on conventional and biologic DMARDs commonly used to treat RA, to broadly document the impact of new therapeutic agents alongside more traditional products. While the conventional and biologic agents included have approved indications besides RA, their pricing is independent of the indication for use and trends will be applicable to RA care costs.

Methods {#sec0002}
=======

Study design {#sec0003}
------------

The current study was an observational study assessing national trends in spending on disease modifying agents used for rheumatoid arthritis using aggregated Medicare data.

Setting & participants {#sec0004}
----------------------

Medicare provides health insurance coverage to individuals greater than 65 years of age and those who are younger but disabled in the US. In 2018 (2019 Annual Report of Medicare Trustees), Medicare provided health insurance for over 60 million individuals, more than 52 million of whom were people aged 65 and older. Medicare provides coverage for prescription medications which are self-administered injections or oral drugs, via Part D, and medications administered as infusions or other office administered agents via Part B. Both Parts D and B are optional benefits for Medicare enrollees and require monthly premiums. For the current study, we used data from CMS\'s annual, publicly available reports (CMS Medicare Part B and Part D Drug Spending Dashboard, available through the [www.cms.gov](http://www.cms.gov){#interref0001} website) of spending on both conventional and biologic disease modifying agents approved for rheumatoid arthritis between 2012 and 2017 which included spending across all ages.

Data sources and variables {#sec0005}
--------------------------

We included all the commonly used disease modifying agents used for rheumatoid arthritis captured through Part B (office-administered) and Part D (self-administered drugs) claims. Conventional agents were methotrexate, sulfasalazine, hydroxychloroquine and leflunomide. Biologic DMARDs available during the period included etanercept, abatacept, adalimumab, certolizumab, golimumab, inflixiumab, rituximab, tocilizumab, and tofacitinib. All conventional DMARDs have been available as generic agents and approved several years before 2012. All the biologic DMARDs were approved for use in RA prior to 2012 except for office-administered certolizumab and golimumab, both approved in 2014. Hence, there was at least 4 years of data to assess the trend of spending on each drug.

The dataset contains aggregated national level spending on individual drugs administered through part D and part B (without any administration fee for part B drugs). CMS data summarizes expenditures total spending which includes amounts paid by Medicare, beneficiaries as deductibles and copayments and third parties (for e.g. supplemental insurances). It also includes beneficiary counts, total claims, total dosage units, average cost per unit (calculated as total spending/total dosage units), average spend per claim, average spending per beneficiary, and changes over time at the brand or generic drug name level. Their data combines utilization/cost data across dosage forms to the product brand, if applicable, or generic, if multisource, name.

Analysis {#sec0006}
--------

We summed spending for brand and generic versions of drug products for each drug. For the conventional DMARD\'s, we used the unit price of the most commonly used formulation as reported by CMS. Unit cost was calculated by dividing the total spending on a particular drug formulation by the number of doses dispended and was available in the data. To examine the trends in unit cost of biologic DMARDs and to compare the costs of these drugs with each other, we calculated the annual expenditure of a maintenance regimen of biologic agents for a typical 70-year-old rheumatoid arthritis patient (regimens discussed in supplementary file 1). This was not possible for conventional DMARDs because of lack of information of drug strength. We presented the trends in total spending on individual drugs between 2012 and 2017, along with trends of unit cost of these agents. We also compared the actual drug prices of individual drugs in 2017 to the prices that would be expected because of inflation alone. The latter was calculated using the medical care component inflation provided by Bureau of Labor Statistics and base price of the drug in 2012 [@bib0021].

Results {#sec0007}
=======

From 2012--2017, Medicare experienced a 2.3-fold increase in their expenditures for DMARDs frequently used for RA: \$4.4 billion in 2012 to \$10.0 billion in 2017. Biologic DMARDs accounted for \~95% of the total expenditure each year.

Between 2012 and 2017, the total spending on the conventional DMARDs increased from approximately \$98 million to \$579 million ([Fig. 1](#fig0001){ref-type="fig"} ). The number of beneficiaries using conventional DMARDs also increased (738,195 to 1,134,094 or 1.5-fold) over the same time period. Increases in unit costs drove the rise in total spending, most notably for hydroxychloroquine where cost/unit increased from \$0.29 to \$1.84. A new brand name hydroxychloroquine product was approved in 2014 with a unit cost of \$8.40 in 2017. Unit cost also nearly tripled for methotrexate and leflunomide. Prefilled methotrexate injections cost between \$344--\$376 per injection, compared to the generic product at \$1.63 per dose ([Table 1](#tbl0001){ref-type="table"} ). The cost of each in 2017 surpassed the expected cost based on inflation alone except for branded oral and injectable methotrexate.Fig. 1Trends in Total Medicare Spending on conventional DMARDs used for RA between 2012--2017.Fig. 1Table 1.Unit Cost paid by Medicare of conventional DMARD used for RA between 2012--17.Table 1:Drug Name2012 (Actual Cost)2017 (Actual Cost)2017 (2012 cost in 2017 dollars)Percentage Increase in Adjusted costs from 2012 to 2017Leflunomide- Generic\$1.68\$4.31\$1.92124%- Branded\$22.49\$38.49\$25.6550%Methotrexate- Generic (oral)\$0.64\$1.89\$0.73159%- Branded (oral)[\*](#tb1fn1){ref-type="table-fn"}\$9.60\$10.01\$10.95-9%- Branded (injectable)[⁎⁎](#tb1fn2){ref-type="table-fn"}\$334.90\$375.90\$381.91-2%Hydroxychloroquine- Generic\$0.29\$1.84\$0.33458%- Branded\$4.18\$8.40\$4.7776%Sulfasalazine\$0.16\$0.19\$0.186%[^1][^2]

Medicare spending on biologic DMARDs more than doubled from \$4.3 billion (2012) to \$10.04 billion (2017), also outpacing the gain in the number of beneficiaries using these products (252,225 to 335,960, 1.3-fold increase) ([Fig. 2](#fig0002){ref-type="fig"} ). There was nearly a doubling in the price per unit of most self-administered biologic DMARDs, and the increase in unit cost of office administered DMARDs was less pronounced, except for abatacept. [Table 2](#tbl0002){ref-type="table"} represents spending for maintenance regimen of biologics for an average 70 kg patient with RA, a function of unit price of the drug. The cost of each drug in 2017 surpassed the expected cost based on inflation alone except for injectable golimumab.Fig. 2Trends in Total Medicare Spending on biologic DMARDs used for RA between 2012--2017.Fig. 2Table 2.Average cost of Maintenance Regimen of each of the biologic DMARDs between 2012--2017.Table 2:Drug Name2012 (Actual Cost)2017 (Actual Cost)2017 (2012 cost in 2017 dollars)Percentage Increase in Adjusted costs from 2012 to 2017SELF ADMINISTERED DRUGSGolimumab\$52,506\$93,961\$59,87757%Adalimumab\$26,491\$58,135\$30,21092%Etanercept\$25,875\$56,897\$29,50793%Abatacept\$27,087\$50,314\$30,88963%Tocilizumab[⁎⁎](#tb2fn2){ref-type="table-fn"}\$27,056\$47,155\$30,85453%Tofacitinib\$25,616\$46,377\$29,21259%Certolizumab\$26,036\$45,830\$29,69154%OFFICE ADMINISTERED DRUGSAbatacept\$19,494\$41,652\$22,23187%Certolizumab[\*](#tb2fn1){ref-type="table-fn"}\$30,992\$38,116\$35,3438%Rituximab\$24,588\$32,549\$28,04016%Tocilizumab\$23,520\$28,358\$26,8226%Infliximab\$17,769\$23,400\$20,26315%Golimumab[\*](#tb2fn1){ref-type="table-fn"}\$23,138\$23,804\$26,836-8%[^3][^4]

Medicare spending on office/infusion center administered drugs declined as a percentage of total spending on biologic DMARDs from 64.3% (\$2.79 billion of 4.3 billion in 2012) to 45.2% (\$4.5 billion of 10.04 billion in 2017). There was a decline in the percentage of total beneficiaries on office/infusion center administered biologic DMARDs. Finally, adalimumab was the most utilized drug amongst beneficiaries receiving biologic DMARDs (73,022 in 2017; 21% share) and had the highest share of total spending (\$2.64 billion in 2017; 26% share).

Discussion {#sec0008}
==========

Between 2012 and 2017, there was a tremendous increase in spending on both biologic and conventional DMARDs used for the treatment of RA without a similar increase in the number of beneficiaries receiving these treatments. And as expected, most of the spending was on biologic DMARDs. The increase in spending was largely driven by increases in cost/unit of individual drugs; for each conventional and biologic DMARD, the actual cost of drug in 2017 was higher than the estimated cost of drug based on medical care component inflation provided by the consumer price index [@bib0022]. The study provides important insights into the spending pattern on individual DMARDs.

We noted that, over the study period, there was a tremendous relative increase in total spending on conventional synthetic DMARDs, almost entirely driven by cost/unit of these drugs and outpacing inflation. The cost/unit of hydroxychloroquine, methotrexate and leflunomide increased almost 3-fold, most notably for hydroxychloroquine which increased 6-fold even though these medications have been available for several decades as generics. Branded oral and injectable methotrexate were the only agents whose actual cost in 2017 was lower than what would be expected by inflation alone. A study by Joyce et al noted an overall decline in the prices of generic medications between 2006 and 2015 covered under the Medicare part D program, however, there were a subset of drugs which saw a tremendous increase during the same time frame [@bib0023]. Lack of or limited availability of competitors seemed to be the primary reason for the rise of such costs [@bib0024]. In the RA treatment algorithms, there are a limited number of conventional DMARDs to choose from. Biologic DMARDs, on the other hand, are considerably more expensive than conventional DMARDs, hence providing an opportunity to manufacturers of conventional DMARDs to increase the unit cost of these agents.

During the same period, there was also a considerable increase in the total spending on biologic DMARDs; the proportion of spending and beneficiaries on self-administered biologics compared to office-administered biologics increased during the study period. Across all biologic agents, the unit cost of office administered agent increased less than the unit cost of self-administered agents. As such, when drug administration costs are factored in, office administered agents are considerably more expensive than self-administered agents. Across all biologic agents, the price of drug in 2017 was much higher than what would be anticipated with inflation using the 2012 base cost except for office administered golimumab. Biosimilar agents were in their early approval phases during the year 2012---17 and hence their effects could not be examined. It could be anticipated that these costs would continue to remain high considering the lengthy process of development, regulatory restrictions, patent laws, and clinical trials required to demonstrate safety and efficacy of biosimilar agents \[[@bib0025],[@bib0026]\].

Hydroxychloroquine is being extensively investigated as a potential therapeutic option for the treatment of COVID-19 caused by the novel coronavirus (SARS-CoV2) [@bib0027], [@bib0028], [@bib0029], [@bib0030]. The global pandemic affecting almost 10 million individuals globally and 2.4 million in the US created an excessive demand for hydroxychloroquine. Tocilizumab and some of the other biologic agents are also being investigated for treatment of COVID-19 [@bib0031], [@bib0032], [@bib0033]. The added demand on these agents may further drive up the unit costs of these medications.

While this study provides useful insights into the spending trends on conventional and biologic DMARDs by Medicare, there are certain limitations that merit discussion. First, we were unable to identify the indications for use of biologic agents. There have been increasing indications of for use of several of the agents for other autoimmune conditions like other inflammatory arthritis, malignancy (for rituximab), uveitis, inflammatory bowel disease and hidradenitis. However, rheumatoid arthritis is the most common inflammatory arthritis amongst senior and hence, most of the spending is likely to be on rheumatoid arthritis. Second, we are unable to assess rebates provided by the pharmaceutical industry to pharmacy benefits manager and Part D plans. Finally, given the categorization of several conventional DMARDs like methotrexate tablets and methotrexate injections under "methotrexate sodium" OR leflunomide 10 mg and 20 mg under "leflunomide", precluded our ability to calculate annual costs different drug regimens like that for biologics.

Despite the limitations, the study provides useful national trends of spending on disease modifying agents in the United States. The findings of this study call for a 2-fold action. First, as the population ages, it is expected that the number of beneficiaries covered through Medicare will increase. If the post-marketing unit costs of DMARDs continue to increase at the pace noted in this study, with the increasing number of Medicare beneficiaries, the total spending on these agents increase at an even faster pace. Hence, policy changes targeting the post-marketing drug prices are required. Second, further studies are required to answer the central question, is the increased spending on DMARDs, particularly biological agents, resulting in improved outcomes in older RA patients. There is growing long-term data to suggest increasing safety of these medications, at least in average RA patients. However, outcomes of interest to geriatric population continue to remain an understudied area in RA care.
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[^1]: indicates drugs that ceased to be covered in 2016;

[^2]: indicates drugs that were approved in 2014

[^3]: indicates drugs that were approved in 2014;

[^4]: Tocilizumab was approved in October 2013 and hence figures of 2014 provided.
